Moreover, in urothelial carcinoma, whether EGFR mutation should be considered an oncogenic driver as well as the therapeutic management in the case of uncommon EGFR mutation associated with comutations remains also unclear. This evidence concerns the gene EGFR and urothelial carcinoma.